ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes

This study is currently recruiting participants.
Verified by Melbourne Health, January 2007

Sponsors and Collaborators: Melbourne Health
Diabetes Vaccine Development Centre
Information provided by: Melbourne Health
ClinicalTrials.gov Identifier: NCT00336674
  Purpose

In people with type I diabetes the beta cells of the pancreas no longer make insulin because the body's immune system has attacked and destroyed the beta cells. It is thought that exposure of the mucous membranes to insulin may cause act like a vaccine effect whereby protective immune cells are stimulated and these then counteract the “bad” immune cells that damage the beta cells. This study aims to determine if intranasal insulin can protect beta cells and stop progression to diabetes in individuals who are at risk.


Condition Intervention Phase
Type 1 Diabetes
Biological: Intranasal insulin
Phase II

MedlinePlus related topics:   Diabetes    Diabetes Type 1   

ChemIDplus related topics:   Insulin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Randomised, Double-Blind, Placebo-Controlled Trial of Intranasal Insulin (1.6mg and 16mg) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II

Further study details as provided by Melbourne Health:

Primary Outcome Measures:
  • Diagnosis of Diabetes AT 5 years according to ADA/WHO criteria.

Secondary Outcome Measures:
  • B cell function: measured as FPIR yearly and
  • glucose and insulin responses in OGTT 6monthly.
  • Insulin Action: Insulin resistance measured by HOMA-R 6 monthly.
  • Immune function: measured by levels of circulating antibodies to insulin, GAD and IA-2 and T cell responses to proinsulin, denatured insulin, GAD and tetanus at 5 years.

Estimated Enrollment:   264
Study Start Date:   December 2006
Estimated Study Completion Date:   December 2012

  Eligibility
Ages Eligible for Study:   4 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  1. First-degree or second-degree relative of a person with T1D diagnosed before age 40.
  2. Age 4-30 years if first-degree relative; age 4-20 years if second-degree relative.
  3. Confirmed serum antibodies to two or more islet antigens.
  4. HLA not DR2, DQ6.
  5. Normal oral glucose tolerance test (OGTT).
  6. FPIR at or above threshold: greater than or equal to 10th percentile for siblings, offspring and second-degree relatives of person with T1D (greater than or equal to 100uU/ml if aged 8 or more years OR greater than or equal to 60 uU/ml if aged less than 8) and greater than or equal to the 1st percentile for parents of someone with T1D (greater than ore equal to 60uU/ml).
  7. Provision of written consent. -

Exclusion Criteria:

  1. History of treatment with insulin or oral hypoglycemic agents
  2. Known diabetes by ADA/WHO criteria
  3. Pregnant or lactating or of child-bearing potential not using an adequate method of contraception
  4. Concomitant disease or treatment which may interfere with assessment or cause immunosuppression, as judged by the investigators.
  5. Uncorrected vitamin D deficiency
  6. Known alcohol or drug abuse, psychiatric or other condition that could be associated with poor compliance.
  7. Known liver disease, or persisting elevation of plasma AST or ALT levels.
  8. Impaired renal function
  9. Any defect or pathology of nasal passage which would preclude application of the intranasal spray.

    -

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00336674

Contacts
Contact: Professor Leonard C Harrison, MD DSc FRACP     61 3 9345 2461     harrison@wehi.edu.au    

Locations
Australia, Victoria
Royal Melbourne Hospital     Recruiting
      Melbourne, Victoria, Australia, 3050
      Principal Investigator: Leonard C Harrison, MD DSc FRACP            

Sponsors and Collaborators
Melbourne Health
Diabetes Vaccine Development Centre

Investigators
Principal Investigator:     Leonard C Harrison, MBBS MD DSc     Melbourne Health    
  More Information

Study ID Numbers:   INIT II
First Received:   June 12, 2006
Last Updated:   March 8, 2007
ClinicalTrials.gov Identifier:   NCT00336674
Health Authority:   Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Melbourne Health:
Type 1 diabetes  

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Hypoglycemic Agents
Immune System Diseases
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 04, 2008




Links to all studies - primarily for crawlers